Jiving with Jazz after $325M opt-in, Zymeworks links HER2 bispecific to 84% survival after 18 months
https://www.fiercebiotech.com/biotech/jiving-jazz-after-325m-opt-zymeworks-links-her2-bispecific-84-survival-after-18-months
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.